PA-BOOMI
16.5.2023 16:01:30 CEST | Business Wire | Press release
BoomiTM, the intelligent connectivity and automation leader, today announced Boomi AI – a first-of-its-kind, simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations – creating business outcomes faster than ever before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005335/en/
Boomi Changes the Integration and Automation Game With Boomi AI (Graphic: Business Wire)
“The introduction of Boomi AI marks yet another milestone in our long history of pioneering innovation in the integration industry,” said Ed Macosky, Chief Product Officer at Boomi. “We pioneered the first low-code, cloud-native integration platform as a service (iPaaS) to disrupt the middleware market 20+ years ago. Then, over a decade ago, Boomi pioneered AI-assisted development with the launch of Boomi Suggest, which further disrupted the market. Now, we are taking our intelligent integration and automation platform to the next level by making it AI-first – enabling AI to responsibly build and complete integrations, and transform automation for our customers.”
In today’s constantly changing market, organizations are making substantial investments to modernize their digital operations. According to IDC, global spending on AI will increase by 26.9% in this next year alone. However, disconnected ecosystems make it difficult for IT teams to focus on strategic initiatives. Fragmented tools, applications, and data can cause confusion and coordination issues, as teams lack a centralized platform for integration, API management, orchestration, and automation, resulting in time spent on maintenance, not innovation.
Boomi’s AI engine is fueled by the company’s approximately 20,000 customers – the largest customer base among integration platform vendors. Boomi AI leverages anonymized metadata, patterns, and best practices from the 200 million integrations made with the Boomi platform to train the AI models to create high-quality integrations across various business processes and applications, such as data management, customer experience optimization, or supply chain processes.
“Boomi’s extensive knowledge base makes our AI engine far more advanced than the AI-assisted development tools available today. It also benefits users by continuously testing patterns to ensure optimal integration design and root out risks and errors early, enabling customers to achieve tremendous gains in efficiency, operational improvements, and other desirable business outcomes,” added Macosky.
With Boomi AI, organizations can:
Design Connections: Boomi AI can design integration processes, application programming interfaces, and master data models with built-in best practices from millions of successful use cases, through a quick command, like, “Connect my CRM and invoice systems.”
Optimize Operations: With Boomi AI’s actionable intelligent insights, users can solve problems proactively, facilitate predictive maintenance, automate updates, and allocate optimal resources to enable software to efficiently self-manage itself. These insights, like “A data attribute in Salesforce has changed. Would you like to apply it across your systems?” make previously menial tasks quick and easy.
Orchestrate Experiences: Boomi AI can interpret intent behind desired business outcomes to orchestrate processes across applications. It enhances decision-making, simplifies tasks, and improves engagement while providing audit history and prompts to confirm intent so that decisions and outcomes are always explainable, creating even greater synergies between IT and the business. With a simple prompt like “Automate invoice processing,” IT teams and business leaders can focus on what matters most.
Enable Responsible AI Development: Boomi’s AI algorithms are trained to avoid biases and unfairness with established ethical guidelines for the development and use of AI within the Boomi platform. These guidelines confirm that Boomi’s AI technology is used in a transparent and accountable manner, and that it does not violate any ethical principles or laws. Additionally, Boomi has achieved U.S. Federal Risk and Authorization Management Program (FedRAMP) Authorization Moderate, a government-wide program that provides a standardized approach to security assessment. Boomi AI does not store any customer-specific information of any kind.
“In today's fast-paced market, organizations need more powerful tools that enable them to outperform, and AI presents a potent new avenue to do this,” says Dion Hinchcliffe, VP and Principal Analyst of Constellation Research. “By embracing an important new AI-first approach, organizations can unlock new levels of efficiency, innovation, and competitive advantage, to immediately capture opportunity as well as ensure their business remains future-ready.”
As the pioneer of cloud-native integration platform as a service (iPaaS), Boomi celebrates a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of partners, including Accenture, Deloitte, SAP, and Snowflake; and works with the largest hyperscaler cloud service providers, including Amazon Web Services, Google, and Microsoft, among others.
Included on the Deloitte Technology Fast 500™ and Inc. 5000 lists as one of America’s fastest growing and most innovative technology companies, Boomi was recently named to Nucleus Research's list of “Hot Companies to Watch in 2023.” The company has also won numerous awards, including three International Stevie® Awards, for Company of the Year (two years in a row) and Product Innovation; the Gold Globee® Award in the Platform as a Service (PaaS) category; the Merit Award for Technology in the Cloud Services category; the Stratus Award as a Global Leader in Cloud Computing 2022; and received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years.
Join the Boomi AI waitlist at boomi.ai.
Additional Resources
- Read more about accelerating outcomes with Boomi AI
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
